|
Market Closed -
Nasdaq
23:00:00 11/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 9.850 USD | -0.66% |
|
-0.51% | +60.16% |
| 08-14 | ImmuCell Corporation, Q2 2026 Earnings Call, Aug 14, 2026 | |
| 08-13 | ImmuCell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: ImmuCell Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 42.92 | 61.94 | 47.26 | 39.45 | 45.89 | 55.63 |
| Change | - | 44.32% | -23.7% | -16.51% | 16.33% | 21.22% |
| Enterprise Value (EV) 1 | 45.7 | 62.02 | 53.94 | 55.16 | 57.24 | 65.02 |
| Change | - | 35.71% | -13.03% | 2.26% | 3.76% | 13.6% |
| P/E | -42x | -776x | -18.9x | -6.79x | -19.5x | -51.3x |
| PBR | 1.52x | 1.9x | 1.56x | 1.58x | 1.68x | 2.06x |
| PEG | - | 8.4x | -0x | -0x | 0.3x | 0.9x |
| Capitalization / Revenue | 2.8x | 3.22x | 2.55x | 2.26x | 1.73x | 2.01x |
| EV / Revenue | 2.98x | 3.22x | 2.91x | 3.16x | 2.16x | 2.35x |
| EV / EBITDA | 47.3x | 22.8x | 286x | -22x | 39.4x | 12.6x |
| EV / EBIT | -33.1x | 241x | -23.5x | -10.6x | -46.4x | 26.5x |
| EV / FCF | -21.2x | -37.9x | -11.7x | -12.2x | 55.7x | 65.1x |
| FCF Yield | -4.72% | -2.64% | -8.54% | -8.17% | 1.8% | 1.54% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.1417 | -0.0103 | -0.322 | -0.75 | -0.2641 | -0.12 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 15.34 | 19.24 | 18.57 | 17.47 | 26.49 | 27.64 |
| EBITDA 1 | 0.9669 | 2.719 | 0.1886 | -2.504 | 1.454 | 5.179 |
| EBIT 1 | -1.38 | 0.2574 | -2.299 | -5.221 | -1.233 | 2.449 |
| Net income 1 | -1.022 | -0.0783 | -2.494 | -5.775 | -2.157 | -1.04 |
| Net Debt 1 | 2.787 | 0.089 | 6.688 | 15.71 | 11.34 | 9.388 |
| Reference price 2 | 5.950 | 8.000 | 6.100 | 5.090 | 5.150 | 6.150 |
| Nbr of stocks (in thousands) | 7,213 | 7,742 | 7,747 | 7,751 | 8,912 | 9,046 |
| Announcement Date | 3/30/21 A | 3/30/22 A | 3/29/23 A | 4/1/24 A | 3/28/25 A | 3/30/26 A |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 89.46M | |
| 31.77x | 11.54x | 23.41x | 0.62% | 994B | |
| 29.54x | - | - | 2.02% | 640B | |
| 32.92x | 7.63x | 15.78x | 2.67% | 454B | |
| 18.71x | 4.57x | 11.31x | 2.91% | 337B | |
| 19.41x | 5.08x | 12.59x | 3.21% | 261B | |
| 20.34x | 4.19x | 11.96x | 2.11% | 246B | |
| 23.87x | 6.3x | 11.23x | 2.67% | 204B | |
| 12.3x | 4.48x | 9.37x | 4.08% | 190B | |
| -43.47x | 6.35x | 24.81x | 2.29% | 178B | |
| Average | 16.16x | 6.27x | 15.06x | 2.51% | 350.49B | |
| Weighted average by Cap. | 23.19x | 7.72x | 17.10x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ICCC Stock
- Valuation ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions
